Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Walmart Stores Inc (WMT) Price & Performance

Merck & Co., Inc.Trade
Walmart Stores IncTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Walmart Stores Inc — how do they compare? Merck & Co., Inc. trades at $132.84 (market cap $321.77B), while Walmart Stores Inc trades at $115.32 (market cap $901.33B). The key difference: Walmart Stores Inc is far larger — about 2.8× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

MRKWMT
Market Cap
$321.77B$901.33B
Sector
HealthConsumer Staples
52-Week High
$131.84$134.20
52-Week Low
$77.60$96.05
Enterprise Value
$368.53B$964.78B
Dividend Yield
2.61%0.87%
Volume
5,675,288

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Walmart Stores Inc

Walmart (WMT) trades at $112.66, up 0.72% with strong fundamental performance including three consecutive quarterly EPS beats and robust revenue growth to $681B in 2025. The stock shows neutral technical signals with RSI at 62.52, while analyst consensus remains strongly bullish with a $142 price target. Recent developments include AI tool innovations and expanded delivery services positioning the company for continued market leadership.

Walmart presents a compelling investment case with solid fundamentals and analyst support, though valuation multiples appear elevated. Key opportunities include sustained revenue growth and operational efficiency gains, while risks involve competitive pressures from Amazon and potential margin compression. The stock offers 26% upside to consensus targets but requires monitoring of execution against high expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Walmart Stores Inc

Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.

Read more on WMT